| Literature DB >> 29425184 |
Tae-Jin Lee1, Min Suk Shim2, Taekyung Yu3, Kyunghee Choi4,5, Dong-Ik Kim6, Soo-Hong Lee7, Suk Ho Bhang8.
Abstract
Entities:
Keywords: SDF-1α; angiogenesis; bioreducible polymer; gene therapy; hADSCs
Mesh:
Substances:
Year: 2018 PMID: 29425184 PMCID: PMC5855751 DOI: 10.3390/ijms19020529
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1(A) Scheme of the synthesis of acid-degradable PEG-PAK; (B) Transmission electron microscopy images of SDF-1α/PEG-PAK micelles before and after acid hydrolysis (pH 5.0 for 8 h at 37 °C, scale bars indicate 200 nm) and confocal laser scanning microscopy images showing the intracellular colocalization of Alexa Fluor 488-labeled SDF-1α pDNA (green) and Cy3-labeled PEG-PAK (red) in hADSCs (blue indicates nuclei stained with DRAQ5, scale bar indicates 10 μm); (C) RT-PCR analysis and (D) quantification of SDF-1α expression in hADSCs transfected with SDF-1α using various methods under hypoxic culture conditions (* p < 0.05 compared with SDF-1α-PEG-PAK group). PEG-PAK: poly(ethylene glycol)-poly(amino ketal); SDF-1α: stromal cell-derived factor-1α; RT-PCR: reverse transcription-polymerase chain reaction; hADSCs: human adipose-derived stem cells; GFP: green fluorescence protein.
Figure 2Apoptotic activity and pro-angiogenic growth factor secretion in hADSCs transfected with SDF-1α using PEG-PAK micelles. (A) RT-PCR analysis of the anti-apoptotic factor Bcl-2 and the pro-apoptotic factor p53 and (B) quantification of their expression in hADSCs transfected with SDF-1α using various methods. (C) Total amount of DNA in each group showing relative cell viability. Relative levels of (D) SDF-1α, (E) VEGF, and (F) FGF2 secretion by hADSCs transfected with SDF-1α using various methods. Secretion was quantified via enzyme-linked immunosorbent assays. (*,# p < 0.05 compared with SDF-1α-PEG-PAK group). VEGF: vascular endothelial growth factor; FGF2: basic fibroblast growth factor.
Figure 3Western blot analysis and quantification of (A) SDF-1α and (B) VEGF expression in the mouse hindlimb ischemia model 3 days after the various treatments; (C) Immunofluorescence staining of caspase-3 (green) and HNA (red) in ischemic limb tissues retrieved 3 days after treatment (blue indicates nuclei stained with 4′,6-diamidino-2-phenylindole (DAPI), scale bar = 100 μm). Percentages of (D) caspase-3-positive cells (apoptotic cells) among DAPI-positive cells (total cells) and (E) HNA/caspase-3 double-positive cells (apoptotic hADSCs) among HNA-positive cells (hADSCs) in the ischemic region (* p < 0.05 compared with PEG-PAK + hADSC group); (F) RT-PCR analysis of human and mouse Bcl-2 (anti-apoptotic factor) and p53 (pro-apoptotic factor) in ischemic limbs.
Figure 4(A) Hematoxylin and eosin staining of hindlimb tissues obtained 21 days after ischemic injury (scale bars indicate 100 µm). (B) Representative laser Doppler perfusion imaging analysis performed at 21 days after treatment. (C) Blood perfusion of ischemic limbs relative to that of normal limbs at 0, 7, 14, and 21 days after treatment (* p < 0.01 compared with other groups). (D) Percentage of mice displaying limb salvage at 21 days after treatment.
Figure 5Representative immunohistochemical images of microvessels positive for (A) CD31 (red) and (B) smooth muscle (SM) α-actin (red) retrieved from hindlimb tissues 21 days after treatment (blue indicates nuclei stained with DAPI, scale bars indicate 100 µm). Quantification of microvessels positive for (C) CD31 and (D) SM α-actin in hindlimb tissues (* p < 0.05 compared with PEG-PAK + hADSC group); (E) Western blot analysis and quantification of (F) ICAM, (G) VCAM, and (H) NG2 expression in hindlimb tissues at 21 days after treatment. ICAM: intercellular adhesion molecule; VCAM: vascular cell adhesion molecule.
Figure 6Western blot analysis and quantification of CD34 expression in ischemic hindlimb tissues at 7 and 21 days after treatment (* p < 0.05 compared with PEG-PAK + hADSC group).